Literature DB >> 17011374

A prospective study of the beneficial effects of dose optimization and customized instructions on patient satisfaction with sildenafil citrate (Viagra) for erectile dysfunction.

Andrew R McCullough1, Culley C Carson, Dimitrios Hatzichristou.   

Abstract

Our objective was to assess the effects of customized instructions and dose optimization on treatment satisfaction and improvement in erectile function (EF) with sildenafil citrate in men with erectile dysfunction (ED) who had not been previously treated with a phosphodiesterase-5 inhibitor. This 8-week, multicenter, open-label, flexible-dose (25, 50, or 100 mg sildenafil) study included 2 phases. During phase 1, patients took 50 mg sildenafil and followed the sildenafil sample package instructions. In phase 2, sildenafil dose could be adjusted on the basis of efficacy and tolerability, and investigators provided additional customized instructions. The primary efficacy variable was the satisfaction rate (defined as patients responding "very" or "somewhat" satisfied to the Erectile Dysfunction Inventory of Treatment Satisfaction [EDITS] Question 1). Other efficacy assessments included the International Index of Erectile Function (IIEF) and the percentage of successful sexual intercourse attempts. Of 1109 men (mean age, 54+/-13 years) treated, 867 completed the study. In phase 1, 75% of patients were very or somewhat satisfied with treatment. Mean EF domain score on the IIEF increased from 14.3 at baseline to 23.5, and 79% of sexual intercourse attempts were successful. In phase 2, 53% of patients increased their sildenafil dose to 100 mg and 2% decreased to 25 mg. Satisfaction with sildenafil increased to 86%, 91% of sexual intercourse attempts were successful, and mean IIEF EF domain score increased to 25.7. Of the 196 men who were not initially satisfied at the end of phase 1, 64% became very or somewhat satisfied with treatment by the end of phase 2. Initially high levels of efficacy and satisfaction with sildenafil were achieved when patients were provided with only the sample package instructions and the recommended 50-mg starting dose. These results were enhanced with dose optimization, individual patient counseling, and customized instructions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011374     DOI: 10.1016/j.urology.2006.04.040

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  Hardness, function, emotional well-being, satisfaction and the overall sexual experience in men using 100-mg fixed-dose or flexible-dose sildenafil citrate.

Authors:  P Ströberg; J C Kaminetsky; N C Park; E R Goldfischer; D L Creanga; V J Stecher
Journal:  Int J Impot Res       Date:  2010-07-01       Impact factor: 2.896

2.  Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction.

Authors:  Konstantinos Giannitsas; Angelis Konstantinopoulos; Christos Patsialas; Petros Perimenis
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

Review 3.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

4.  Improvement in erection hardness and intercourse success with first dose of sildenafil citrate 100 mg.

Authors:  John P Mulhall; Dana L Creanga; Vera J Stecher
Journal:  Int J Gen Med       Date:  2013-11-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.